Finally, an ongoing feasibility phase I study is currently examining different sequences of combined trastuzumab emtansine (TDM-1) and WBRT in patients with BM from HER2-positive BC (brain radiation and TDM-1 in HER2-positive metastatic BC: BIRTH trial). Here, ERBB2 is linked to breast cancer.